New Molecule UNI418 Reverses Cancer Drug Resistance by Disabling DNA Repair

Researchers at the Institute for Basic Science have identified a promising strategy to combat cancer drug resistance by targeting the cellular machinery responsible for DNA repair. Many cancer cells evade chemotherapy and PARP inhibitors by utilizing robust repair mechanisms, such as homologous recombination, to fix genetic damage. By destabilizing these repair pathways, scientists have found a way to render previously resistant tumors vulnerable to treatment once again.

The core of this discovery is a small molecule known as UNI418. Through a specialized screening process, the research team observed that UNI418 significantly reduces the levels of critical DNA repair proteins, specifically RAD51 and CHK1. Without these essential components, cancer cells lose their ability to mend damaged DNA, effectively neutralizing their primary defense mechanism against therapeutic intervention.

Mechanistically, UNI418 functions by manipulating the cell’s internal protein disposal system. The molecule interferes with inositol phosphate metabolism, leading to a decrease in IP6, a regulator that normally keeps the Cul4A ubiquitin ligase complex in check. Once this restraint is removed, the Cul4A complex—assisted by the adaptor protein WDR5—targets and destroys the proteins necessary for DNA repair. This process forces the cancer cells into a state of repair deficiency, making them susceptible to treatments that they had previously learned to bypass.

This breakthrough offers a significant shift in oncology, moving beyond the traditional focus on genetic mutations to target the regulatory pathways of protein stability. By successfully re-sensitizing resistant cancer cells to PARP inhibitors, this approach provides a potential roadmap for developing combination therapies that could improve long-term outcomes for patients facing aggressive, treatment-resistant malignancies.